BBB+/Baa1 Dual Ratings Secure Sun Pharma's Path to ₹11.75B Organon Takeover

The Quick Take

• S&P assigned BBB+ and Moody's assigned Baa1 long-term ratings to Sun Pharma for the Organon acquisition
• Investment-grade ratings unlock global bond market access to fund the ₹11.75 billion overseas deal
• Dual ratings from both major agencies signal strong confidence in Sun Pharma's combined entity credit profile

Rating agencies S&P Global and Moody's both assigned investment-grade ratings — BBB+ and Baa1 respectively — to Sun Pharmaceutical Industries in connection with its proposed ₹11.75 billion acquisition of US-based Organon and Co. The simultaneous dual-agency action is significant because it grants Sun Pharma immediate access to the deepest pools of global fixed-income capital, allowing the company to term out acquisition financing at long maturities and competitive spreads unavailable to sub-investment-grade issuers.

The Baa1 and BBB+ ratings place Sun Pharma at the lower end of investment grade, implying that post-acquisition leverage will be meaningful but manageable. Organon's contribution to the combined group — a portfolio of women's health brands plus a growing biosimilar business — provides the cash flow diversity that supported both agencies' scoring. Indian pharmaceutical peers including Cipla, Lupin, and Dr. Reddy's will now face a scale-advantaged competitor with access to cheaper capital, while domestic investors who hold Sun Pharma equity gain insight into the deal's capital structure certainty.

The key forward signal is the deal's financing close and the pricing of the investment-grade bond tranche, which will reveal institutional investor appetite for Indian pharma credit at this scale. The macro variable is US drug pricing regulation under the Inflation Reduction Act — any expansion of CMS Medicare negotiation to Organon's core women's health drugs could impair the revenue assumptions embedded in the agencies' ratings models and force a review of the assigned levels within twelve months of close.

Synthesized from 1 source.